SLC5A2 and COVID-19: Furthermore, some novel antidiabetic drugs, such as SGLT2 inhibitors and GLP1 RAs, routinely employed in T2D management, may exacerbate the clinical expression of COVID-19 and, thus, should be stopped in the most fragile patients.